Please assess the completion status of the following clinical trial:

Trial Title: Curative Efficacy of Pravastatine in Patients Presented Delayed Cutaneous and Subcutaneous Radio-induced Fibrosis

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Grade \>= 2 cutaneous and/or subcutaneous fibrosis (NCI-CTCAE v4 toxicities scale) revealed from 6 to 24 months after head and neck radiotherapy.~2. Head and neck cancers treated by radiation therapy +/- chemotherapy, +/- surgery, with no evidence of progressive disease.~3. Age \>= 18~4. Karnofsky PS ≥ 70~5. normal renal function (plasmatic creatinine \<= 130 micromol/l), normal cholesterol, normal hepatic function (total bilirubin \<= 1.5 UNL, SGOT and SGPT \<= 2 UNL)~6. Written informed consent of the patient.~Exclusion Criteria:~1. any chronic treatment by corticoids~2. severe cardiac pathology~3. patients already treated by statins or treated by fibrates, cyclosporine~4. history of muscular toxicities when treated by fibrates or by statins~5. Personal or familial history of hereditary muscular pathology~6. Plasmatic CPK \>3 UNL~7. patient already included in another therapeutic trial with an experimental drug,~8. pregnant patient or susceptible to pregnancy or breast feeding (patients in age to give birth must be placed under efficient contraception),~9. a social or psychological condition that does not allow a positive patient's participation in the treatment and necessary medical follow-up to be envisaged,~10. the patient is under legal restrained or tutelage.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Pravastatin (Type: EXPERIMENTAL): Pravastatin : 40mg/day during 12 months

Based on this trial design, predict the completion outcome and termination type (if applicable).